Subscribe Become an Author Sign Up Log In
Insilico Medicine


Contact us at to request profile updates/corrections. You must be an official company representative to do so (only requests from corporate emails are accepted).

Insilico Medicine



A company dedicated to finding novel solutions for aging and age-related diseases using advances in genomics and big data analysis.

Our mission statement and our pledge to our investors, friends and families: Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself.

This mission will be achieved within within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility.

Our goals are:

- to become the first and the largest drug discovery company in aging and age-related diseases;
- to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment

Year Founded
Hong Kong based
$51.3 M
Field/area focus
Chemistry and Biology
Research papers
Business model
  • Own Drug Discovery Programs
Therapeutic focus
  • Dermatology
  • Metabolics
  • Neuroscience
  • Oncology
  • Senescence
Data type used for modelling
  • EHRs/lab notebooks/databases (structured data mining)
  • Network biology analysis (omics)
Drug Discovery Strategy
  • Network Analysis, Omics Approach
  • Phenotypic Drug Discovery (PDD)
Product type
  • Biomarkers
  • Small molecules
Research focus
  • Biology research (Target identification/validation)
  • Biomarker Discovery
  • Data mining / Ontology building
  • Drug Repurposing
  • Lead Discovery
  • Preclinical Development

Investing history

2019Series B37.0
2018Seed round6.0
2017Series A2.8
2017Series A4.0
2014Unknown Round1.2
2014Seed round0.3

Industry Partnerships

2017GlaxoSmithKlineidentification of novel biological targets and pathways of interest to GSK
2018WuXi Apptecapply next-generation AI to discover the ideal pre-clinical candidates for novel and challenging biological targets, including orphan targets with no known crystal structure and no known ligands
2019Jiangsu Chia Tai Fenghai PharmaceuticalThe collaboration aims to accelerate drug discovery and development with an AI-enabled platform for triple-negative breast cancer.
2020PfizerUse Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.

Posts Mentioning This Company

Biopharma Insights
Biopharma Insights
Featured Research
New Tools, Products and Technologies
Biopharma Insights
Biopharma Insights
Drug Discovery Insights